Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Oncolytic viruses are potent anticancer agents with demonstrated clinical potential, targeting specific cancers to induce cell death and antitumor immunity.
• Current single-agent oncolytic virotherapy shows modest clinical effects, driving interest in combination therapies.
• Chemotherapeutic agents can also induce systemic antitumor immunity via immunogenic cell death.

Purpose of the Study:

• To review the potential of combining common cytotoxic agents with clinically relevant oncolytic viruses.
• To highlight the synergistic mechanisms and clinical advancements of these combination therapies.

Main Methods:

• Review of existing literature on oncolytic virus and chemotherapy combinations.
• Analysis of in vitro and in vivo studies demonstrating synergistic effects.
• Examination of clinical trial data for combined modality treatments.

Main Results:

• Combination of oncolytic viruses and chemotherapy demonstrates significant in vitro and in vivo synergies.
• These combinations show potential for enhanced antitumor immunity and efficacy.
• No apparent additional toxicities have been observed with combined treatments.

Conclusions:

• Combining oncolytic viruses with chemotherapy represents a promising strategy for advanced cancer management.
• This approach has already progressed to clinical trials, indicating significant therapeutic potential.
• Further research and clinical evaluation are warranted to optimize these combined treatments.